Levetiracetam Tablet, Film Coated
Product Images NDC 68788-8254

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68788-8254). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam Tab Usp 500mg (E31c6830 4647 4481 B4f1 494a52c48b1b 00)

This is a medication label for Levetiracetam Tab USP 500mg, which is a generic version of the anti-epileptic drug Keppra. It contains information about the composition, dosage, expiration date, and lot number of the medication. The label warns against transferring the drug to anyone other than the patient for whom it was prescribed, in compliance with federal law. There is also a billing chart log section present.*

FDA Label Image

Figure 1 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 01)

This text provides a formula to calculate the total daily dose of a medication using the patient's weight and the daily dose in milligrams per kilogram. The medication concentration is provided as 100mg/mL.*

FDA Label Image

Figure 2 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 02)

This text describes a formula used to calculate a patient's renal clearance rate (CLer) for females, based on their age, weight, and serum creatinine levels. The formula also involves an adjustment for body surface area (BSA). However, without more context or information about the specific medical scenario, it is difficult to determine the significance or practical applications of this calculation.*

FDA Label Image

Structure (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 03)

FDA Label Image

Figure 4 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 04)

FDA Label Image

Figure 5 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 05)

This appears to be a table showing the percentage of patients at different levels of treatment for a medical study, with the three treatment groups being Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. However, there is not enough context to determine what condition the study was addressing or what the percentages refer to specifically.*

FDA Label Image

Figure 6 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 06)

FDA Label Image

Figure 7 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 07)

This appears to be a table showing the percentage of patients in a study who received either a placebo or levetiracetam, a medication used to treat seizures. The first column lists the percentages of patients, while the second and third columns describe the number of patients who received the treatment.*

FDA Label Image

Figure 8 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 08)

This text represents the percentage of patients who received either a placebo or Levetiracetam and the number of patients in each group. Specifically, 19.6% of patients (N=51) received a placebo, while 43.1% of patients (N=58) received Levetiracetam.*

FDA Label Image

Figure 9 (E24dd8a7 86c4 4979 8f2e Da2d82f5d6d8 09)

This table represents the percentage of patients in a medical study who were treated with either a placebo or levetiracetam. The percentages range from 0% to 100% in increments of 10%, with the specific percentages shown for each category. The study included 84 patients who received the placebo and 79 patients who received levetiracetam. There is no additional information on the study or condition being treated.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.